Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $10.90, for a total transaction of $17,821.50. Following the transaction, the insider owned 3,594 shares in the company, valued at $39,174.60. This represents a 31.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Scott Bizily also recently made the following trade(s):

• On Monday, November 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.59, for a total transaction of $17,314.65.
• On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00.
• On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.17, for a total transaction of $16,627.95.
• On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $24,080.00.
• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $8.00, for a total transaction of $19,256.00.

4D Molecular Therapeutics Price Performance

NASDAQ FDMT opened at $8.68 on Friday. The stock has a market capitalization of $495.89 million, a price-to-earnings ratio of -2.31 and a beta of 2.96. 4D Molecular Therapeutics, Inc. has a 1-year low of $2.23 and a 1-year high of $12.34. The business’s fifty day moving average price is $10.68 and its 200-day moving average price is $7.53.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.01. The company had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.40 million. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%. Equities research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC grew its position in shares of 4D Molecular Therapeutics by 265.3% during the third quarter. Armistice Capital LLC now owns 1,096,000 shares of the company’s stock valued at $9,524,000 after purchasing an additional 796,000 shares in the last quarter. Wexford Capital LP purchased a new stake in shares of 4D Molecular Therapeutics in the third quarter worth about $41,000. Prelude Capital Management LLC boosted its stake in 4D Molecular Therapeutics by 11.1% during the third quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock valued at $200,000 after buying an additional 2,300 shares during the last quarter. Parkman Healthcare Partners LLC bought a new position in 4D Molecular Therapeutics during the third quarter valued at approximately $1,738,000. Finally, Brevan Howard Capital Management LP purchased a new position in 4D Molecular Therapeutics during the 3rd quarter valued at approximately $143,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Analysts Set New Price Targets

FDMT has been the subject of several recent research reports. Chardan Capital restated a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday. Barclays decreased their target price on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Leerink Partners reissued an “outperform” rating and issued a $17.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Finally, Royal Bank Of Canada lifted their target price on shares of 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, November 11th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $28.70.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.